A Bayesian discretized survival time inference framework in which individualized predictions from potentially multiple external sources are integrated through a formulation based on Kullback-Leibler divergence, yielding informative priors is developed.
Abstract
Prognostic factor evaluation and prediction model development are central to precision oncology, enabling patient risk stratification and individualized treatment selection. Unified predictions that synthesize information from existing models are valuable for comprehensive and consistent risk assessment. Many studies also seek to evaluate the incremental value of new biomarkers beyond established prognostic factors. However, such efforts are often constrained by small-to-moderate sample sizes. Motivated by these challenges, we consider Cox regression analysis in settings where individualized risk predictions from existing models are externally available without a transparent or interpretable structure, for example, through online calculators. We develop a Bayesian discretized survival time inference framework in which individualized predictions from potentially multiple external sources are integrated through a formulation based on Kullback-Leibler divergence, yielding informative priors. The divergence-based formulation serves as a surrogate for the external information likelihood, enabling principled incorporation of individualized predictions without requiring knowledge of the underlying external prediction models. Theoretical results show that the resulting posterior mean estimators are asymptotically more efficient than their internal-only maximum likelihood counterparts. However, using the divergence-based surrogate in place of the unavailable external likelihood renders posterior variance-based inference conservative. We propose a correction to address this overcoverage. We demonstrate the performance of the proposed approach through simulations and an application to prostate cancer trial data.
Identifying variables associated with clinical endpoints is a central objective in clinical trials. With the rapid expansion of cell and gene therapies (CGTs) and therapeutics for ultra-rare diseases, there is an urgent demand for statistical methods capable of detecting meaningful associations under severe sample-size...
Ling-Xuan Kong, Yu-Min Zhang, Chenkun Wang et al.· Journal of Biopharmaceutical...· 0 citations
The survkl software is introduced, which enables the incorporation of external summary-level information with newly collected time-to-event data to support more robust and accurate predictions in survival analysis.
Yu-Bo Shao, Lingfeng Luo, Xiao-Han Liu et al.· Bioinformatics Advances· 0 citations
Background Predictive models are increasingly used in clinical decision-making in coronary artery disease (CAD). However, most existing models focus on discriminative ability while ignoring individual prediction uncertainty, which is particularly prominent in small-sample contexts, limiting clinical applications. Metho...
Sheng-Nan Lin, Xu-Yang Hu, Yang Zhang et al.· Frontiers in Cardiovascular...· 0 citations
Introduction: Cost-effectiveness modeling often requires the extrapolation of survival data from clinical trials. The choice of extrapolation method is often uncertain and can have a profound effect on the results. We propose an approach that incorporates external evidence (eg, from published studies, registries, or el...
David McConnell, Arthur White, F. Lamrock et al.· Medical decision making· 0 citations
Breast cancer risk assessment and prediction models are very important tools for the clinical management of healthy women carrying pathogenic variants in known cancer genes. We propose in this paper a comprehensive prediction model for the personalized clinical management of women with pathogenic variants in {\it BRCA1...
Siriac Seboka, Laurent Briollais, Yun-Hee Choi et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.